Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Orsay – page 20

3 415 clinical trials in Orsay, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Orsay at a glance
3 415
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

3 415 trials in Orsay

Open in trial search

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran hemihydrate
  • Sponsor:Merck Healthcare KGaA

Phase 2 Study of PF-08634404 with Carboplatin and Etoposide in Adults with Untreated Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran hemihydrate
  • Sponsor:Merck Healthcare KGaA

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Astellas Pharma Global Development Inc.

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Merck Sharp & Dohme LLC

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Orsay

What the registry says about research in the country

01 Neurological Studies

Advanced research focusing on neurological disorders including innovative imaging studies for epilepsy, multiple sclerosis, and Huntington's disease. These trials utilize cutting-edge PET-MRI technology to better understand disease progression and treatment effectiveness.

  • Drug-resistant epilepsy imaging
  • Multiple sclerosis inflammation markers
  • Huntington's disease biomarkers

Research aims to improve diagnostic accuracy and treatment planning through advanced imaging techniques.

02 Psychiatric & Mental Health

Innovative studies exploring treatments for mental health conditions, with a focus on early psychosis and severe depression. Trials evaluate novel therapeutic approaches combining medication and digital interventions.

  • Early psychosis treatment
  • Ketamine therapy for depression
  • Personalized care approaches

Research emphasizes personalized treatment strategies and innovative therapeutic combinations.

03 Critical Care Medicine

Studies addressing critical care challenges including septic shock management and specialized treatments for severe medical conditions. Focus on improving patient outcomes in intensive care settings.

  • Septic shock delirium prevention
  • Severe hyponatremia management
  • Ventilator-associated pneumonia

Trials aim to enhance treatment protocols in critical care scenarios.

04 Oncology & Imaging

Advanced research in cancer treatment and diagnostic imaging, particularly focusing on colorectal cancer and CNS lymphoma. Studies utilize innovative imaging techniques for better disease characterization.

  • Colorectal cancer therapy
  • CNS lymphoma imaging
  • PET/MR imaging applications

Research combines cutting-edge imaging with targeted therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.